http://rdf.ncbi.nlm.nih.gov/pubchem/reference/35522153

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 3780
issn 1591-9528
issueIdentifier 7
pageRange 3767-3780
publicationName Clinical and Experimental Medicine
startingPage 3767
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4d0b9f77b45ccd2c7ef27f564f1cfe57
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0699193d1bfd1d30a817f9381824103b
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0bc269c7f9b0816b781df09ff966dfe5
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f970bf1a8a27f190da4710fdc81bb3ff
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_128a54858c94322a22fe100754f3b35f
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a0cd648430cc097fa6c5be3232e05e8c
bibliographicCitation Yang L, Zhao Q, Chen T, Liu W, Qiu X, Chen J, Huang S, Huang R, Dong L. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma. Clin Exp Med. 2023 Nov;23(7):3767–80. doi: 10.1007/s10238-023-01068-3. PMID: 37106265.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b4a92cca648a3d9bbccf4df5e76385f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f55a6aa5d311bb6118d3bd3beeda424b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c701cf0a1dabd2de619e7522420ee6a9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9001ab4669a6d78360ac80eb24006a03
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da71effcf27a095df4849861a46c994e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea41ee74379c1e2395cc39f64faa1a94
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_708cb9e01b482a267bee3187865d9999
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43ec4980516622304291badcb4c0ca3d
date 2023-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1007/s10238-023-01068-3
https://pubmed.ncbi.nlm.nih.gov/37106265
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22294
https://portal.issn.org/resource/ISSN/1591-9528
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
discusses http://id.nlm.nih.gov/mesh/M000675754
http://id.nlm.nih.gov/mesh/M0267456
http://id.nlm.nih.gov/mesh/M000613582
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1b2452da84551fc91db93425b6a20d9
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e5b76014a1846603200cec2b231e3d25
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9859
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7a0153350cba31da4ce6bfa8f8c68f72
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8035
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b491c801eacb22c880cab442689e5524
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8388
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f

Total number of triples: 47.